2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1234

Effects Of Biological Therapy In Bone Metabolism In Patients With Chronic Inflammatory Arthropathies
Abstract Number: 1742

Effects Of Blisibimod, An Inhibitor Of B Cell Activating Factor, On Serum Immunoglobulins and Infection Risk In Patients With Systemic Lupus Erythematosus: Observations From The Placebo-Controlled Pearl-SC and Open-Label Extension Studies
Abstract Number: 2146

Effects Of Chondroitin Sulfate On Brain Response To Painful Stimulation In Knee Osteoarthritis Patients: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Abstract Number: 169

Effects Of Chondroitin Sulfate On The Gene Expression Profile In Interleukin-1β Stimulated Synovial Fibroblast Cells Cultures
Abstract Number: 171

Effects Of Chondroitin Sulfate On The Gene Expression Profile In The Inflamed Synovial Membrane
Abstract Number: 1604

Effects Of Chronic Treatment With Blisibimod, An Inhibitor Of B Cell Activating Factor, On Renal and Inflammation Biomarkers In Patients With Systemic Lupus Erythematosus: Observations From The Placebo-Controlled Pearl-SC and Open-Label Extension Studies
Abstract Number: 539

Effects Of ERAP1 Knockdown On HLA Class I and HLA-B27 Expression In Human Monocytic U937 Cells
Abstract Number: 682

Effects Of Extracoporeal Shock Wave Therapy To The Digital Ulcers Of Scleroderma:a Pilot Study
Abstract Number: 559

Effects Of In Vivo Treatment With Hydroxychloroquine On Endothelial Function In a Murine Model Of Systemic Lupus Erythematosus
Abstract Number: 2140

Effects Of Intra-Articular Hyaluronic Acid Injections On Gait Pattern In Patients With Knee Osteoarthritis
Abstract Number: 2410

Effects Of Leptin and Adiponectin On Proliferation and Activation Were Are Significantly Increased In CD4⁺ T Cells From Rheumatoid Arthritis Patients
Abstract Number: 654

Effects Of Macitentan and Its Active Metabolite In Modulating Extracellular Matrix Synthesis In Cultured Human Systemic Sclerosis and Normal Skin Fibroblasts
Abstract Number: 2452

Effects Of Smoking In Patients With Axial Spondyloarthritis – Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis – Receiving Anti-TNF therapy
Abstract Number: 1404

Effects Of Smoking On Joint Physiology In Men and Mice
Abstract Number: 1418

Effects Of Smoking Status On Response To Treatment With Tofacitinib In Patients With Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].